Glucagon-like Peptide-1 Receptor Agonists and Suicidal Ideation: Analysis of Real-Word Data Collected in the European Pharmacovigilance Database

Rosanna Ruggiero,Annamaria Mascolo,Angela Spezzaferri,Claudia Carpentieri,Daniele Torella,Liberata Sportiello,Francesco Rossi,Giuseppe Paolisso,Annalisa Capuano
DOI: https://doi.org/10.3390/ph17020147
IF: 4.6
2024-01-23
Pharmaceuticals
Abstract:Background: A potential risk of suicide associated with liraglutide or semaglutide treatments has recently emerged. Therefore, we decided to investigate the reporting probability of suicidal events among glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Methods: A retrospective pharmacovigilance study of the European Pharmacovigilance database was conducted for the period from 1 January 2018 to 10 July 2023. Disproportionality analyses (reporting odds ratio, ROR) were performed to assess the reporting probability of suicidal events among GLP-1 RAs. Results: A total of 230 reports of suicidal events were identified. The most reported GLP-1 RA was liraglutide (38.3%), followed by semaglutide (36.5%) and dulaglutide (16.1%). The most reported events were suicidal ideation (65.3%) and suicide attempt (19.5%). Disproportionality analysis found a higher reporting probability of suicidal events for semaglutide than dulaglutide (ROR, 2.05; 95%CI, 1.40–3.01) and exenatide (ROR, 1.81; 95%CI, 1.08–3.05). In the same way, liraglutide was associated with a higher reporting probability of suicidal events than dulaglutide (ROR, 3.98; 95%CI, 2.73–5.82) and exenatide (ROR, 3.52; 95%CI, 2.10–5.92). On the contrary, a lower reporting probability was found for semaglutide than liraglutide (ROR, 0.51; 95%CI, 0.38–0.69). Conclusions: Suicidal events were mostly reported with semaglutide and liraglutide, which were also associated with significantly higher reporting probabilities compared to other GLP1 RAs. Although this study provides the reporting frequencies of suicide-related events with GLP-1 RAs, establishing causality requires further investigation, which will probably be addressed by the Pharmacovigilance Risk Assessment Committee of the European Medicine Agency in the future.
pharmacology & pharmacy,chemistry, medicinal
What problem does this paper attempt to address?
### Problems the paper attempts to solve This paper aims to evaluate the association between glucagon - like peptide - 1 receptor agonists (GLP - 1 RAs) and suicidal ideation by analyzing real - world data in the European pharmacovigilance database. Specifically, the researchers hope to explore the probability of reporting suicide events for different GLP - 1 RAs in actual use through a retrospective pharmacoepidemiological study and assess whether these drugs may increase the risk of suicide. ### Background In recent years, there have been reports of the risk of suicidal ideation in patients treated with liraglutide or semaglutide. To further explore this potential risk, the researchers decided to analyze the relevant data in the European pharmacovigilance database. GLP - 1 RAs are a class of drugs mainly recommended for the treatment of type 2 diabetes mellitus (T2DM). By stimulating GLP - 1 receptors, they can lower blood glucose, increase hyperglycemic - induced insulin secretion and inhibit glucagon release in hyperglycemic or normoglycemic states. Currently, six GLP - 1 RAs have been authorized in Europe, including exenatide, liraglutide, lixisenatide, the liraglutide/insulin degludec combination, dulaglutide and semaglutide. In addition, GLP - 1 RAs are also used for weight management, especially liraglutide and semaglutide have been approved for the treatment of obesity or overweight. ### Research methods The researchers conducted a retrospective pharmacoepidemiological study and analyzed individual case safety reports (ICSRs) in the European pharmacovigilance database from January 1, 2018 to July 10, 2023. The researchers used disproportionality analysis (reporting odds ratio, ROR) to evaluate the probability of different GLP - 1 RAs reporting suicide events. ### Results The study identified a total of 230 ICSRs reporting suicide events. Among them, the most frequently reported GLP - 1 RA was liraglutide (38.3%), followed by semaglutide (36.5%) and dulaglutide (16.1%). The most common events were suicidal ideation (65.3%) and attempted suicide (19.5%). Disproportionality analysis showed that the probability of semaglutide reporting suicide events was higher than that of dulaglutide (ROR, 2.05; 95% CI, 1.40 - 3.01) and exenatide (ROR, 1.81; 95% CI, 1.08 - 3.05). Similarly, the probability of liraglutide reporting suicide events was also higher than that of dulaglutide (ROR, 3.98; 95% CI, 2.73 - 5.82) and exenatide (ROR, 3.52; 95% CI, 2.10 - 5.92). Conversely, the probability of semaglutide reporting suicide events was lower than that of liraglutide (ROR, 0.51; 95% CI, 0.38 - 0.69). ### Conclusions The study found that suicide events were mainly associated with semaglutide and liraglutide, and the probability of these two drugs reporting suicide events was significantly higher than that of other GLP - 1 RAs. Although this study provided the reporting frequency of GLP - 1 RA - related suicide events, further investigation is still required to determine the causal relationship, which may be carried out by the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency in the future.